Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Human PTEN mRNA (ψUTP): Benchmarking Pseudouridin...

    2025-12-18

    EZ Cap™ Human PTEN mRNA (ψUTP): Benchmarking Pseudouridine-Modified Cap1 mRNA for Cancer Research

    Executive Summary: EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA encoding human PTEN, equipped with Cap1 and pseudouridine modifications, designed for robust expression in mammalian systems (APExBIO). The product enables efficient inhibition of the PI3K/Akt signaling pathway, a key axis in tumorigenesis and resistance mechanisms (Dong et al. 2022). Pseudouridine and Cap1 modifications enhance mRNA stability and translation while minimizing innate immune sensing (source). This mRNA is validated for use in nanoparticle-mediated delivery systems for cancer therapy and gene expression studies (source). All handling requires strict RNase-free protocols and cold-chain maintenance for maximal integrity and reproducibility.

    Biological Rationale

    PTEN (phosphatase and tensin homolog) is a well-characterized tumor suppressor gene that negatively regulates the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, a pathway frequently hyperactivated in many cancer types (Dong et al. 2022). Loss or inhibition of PTEN leads to uncontrolled cell proliferation, survival, and tumor progression. Restoring PTEN function is a validated approach to counteract drug resistance, particularly in HER2-positive breast cancer models resistant to trastuzumab (Dong et al. 2022).

    Traditional gene delivery systems face challenges, including poor mRNA stability, immune activation, and inefficient translation (internal link). The development of in vitro transcribed mRNA with chemical modifications such as pseudouridine and advanced capping structures like Cap1 addresses these limitations, enabling more reliable, immunoevasive gene expression (internal link).

    Mechanism of Action of EZ Cap™ Human PTEN mRNA (ψUTP)

    EZ Cap™ Human PTEN mRNA (ψUTP) is a single-stranded RNA transcript, 1467 nucleotides in length, encoding full-length human PTEN. The transcript is modified with pseudouridine (ψ) in place of uridine (U), which suppresses innate immune activation and enhances mRNA half-life (internal link). The Cap1 structure, generated enzymatically using Vaccinia virus capping enzyme, 2'-O-Methyltransferase, GTP, and S-adenosylmethionine (SAM), ensures optimal recognition by eukaryotic ribosomes and avoids detection by cytosolic RNA sensors (APExBIO).

    Upon delivery (e.g., via lipid nanoparticles), this mRNA enters target cells, is translated by host ribosomes, and produces functional PTEN protein. The restored PTEN antagonizes PI3K activity, inhibiting Akt phosphorylation, thereby blocking downstream pro-survival and proliferative signals. This mechanistic pathway is crucial for reversing resistance to targeted therapies such as trastuzumab in HER2-positive breast cancer (Dong et al. 2022).

    Evidence & Benchmarks

    • Pseudouridine-modified mRNA demonstrates increased stability and reduced innate immune activation in mammalian cells (Dong et al. 2022).
    • Cap1-structured mRNAs yield higher translation efficiency versus Cap0 in mammalian systems (source).
    • Restoration of PTEN expression via mRNA delivery blocks PI3K/Akt signaling and reverses trastuzumab resistance in HER2-positive breast cancer models (Dong et al. 2022).
    • EZ Cap™ Human PTEN mRNA (ψUTP) supplied at ~1 mg/mL in 1 mM sodium citrate (pH 6.4) remains stable at -40°C or below, with shipping on dry ice to preserve integrity (APExBIO).
    • Efficient PTEN restoration using this product has been observed in nanoparticle-mediated delivery workflows designed to overcome PI3K/Akt-driven drug resistance (internal link).

    Applications, Limits & Misconceptions

    EZ Cap™ Human PTEN mRNA (ψUTP) is primarily used in preclinical and translational research settings, including:

    • Gene expression studies investigating PTEN function and pathway modulation.
    • Nanoparticle-mediated drug delivery models for cancer therapy (Dong et al. 2022).
    • Functional studies addressing drug resistance mechanisms mediated by PI3K/Akt signaling.

    This article extends prior internal resources by providing a cross-comparison of mRNA stability and translational efficiency benchmarks, as previously outlined in EZ Cap™ Human PTEN mRNA (ψUTP): Benchmarking Cap1 mRNA, and by updating recent literature on nanoparticle-delivered PTEN mRNA for drug resistance reversal (Applied Use-Cases).

    Common Pitfalls or Misconceptions

    • This mRNA is not intended for direct therapeutic use in humans; it is for research purposes only.
    • Direct addition to serum-containing media without a transfection reagent results in rapid mRNA degradation (APExBIO).
    • Repeated freeze-thaw cycles significantly reduce mRNA integrity; aliquoting and cold-chain management are mandatory.
    • PTEN mRNA alone cannot overcome all forms of drug resistance; pathway redundancy or parallel mutations may limit efficacy.
    • RNase contamination during handling leads to irreversible product degradation and experimental failure.

    Workflow Integration & Parameters

    Preparation: EZ Cap™ Human PTEN mRNA (ψUTP) is provided at approximately 1 mg/mL in 1 mM sodium citrate buffer (pH 6.4). Store at -40°C or colder. Aliquot upon receipt to avoid freeze-thaw cycles. Handle exclusively with RNase-free reagents and on ice. Do not vortex.

    Transfection: For mammalian cell culture, combine with a suitable transfection reagent (lipid-based or polymeric nanoparticles). Do not add directly to serum-containing media without complexation.

    Delivery: For in vivo studies, nanoparticle-based delivery is recommended for systemic administration and tumor targeting, as demonstrated in breast cancer reversal models (Dong et al. 2022).

    This article clarifies the optimal workflow for Cap1, pseudouridine-modified mRNA, complementing EZ Cap™ Human PTEN mRNA (ψUTP): Redefining PI3K/Akt Pathway Modulation by providing explicit storage, handling, and transfection parameters for reproducibility.

    Conclusion & Outlook

    EZ Cap™ Human PTEN mRNA (ψUTP) from APExBIO sets a new benchmark for mRNA-based gene expression and cancer research. The combination of Cap1 structure and pseudouridine modification addresses previous limitations in mRNA stability, translation, and immune activation. This product is positioned for continued impact in mechanistic studies and preclinical models targeting the PI3K/Akt pathway and drug resistance in oncology. Future applications may expand with further validation of delivery systems and combinatorial gene modulation strategies.